Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Stephen How who wrote (939)	5/15/1998 9:27:00 AM
From: Jim Roof	Read Replies (1) \| Respond to of 1432

<<Further, as Hextendr does not solve the potential hetastarch-induced coagulopathy problem, it will have the same standing as hetastarch as an alternative to albumin.>> When I bring up the data that, while admittedly not all statistically significant on a per issue basis, does show that Hextend is superior you say that the data cannot be trusted. You then turn around and use the same data and say that Hextend is definitely not superior in any way. How can you be so sure that your interpretation of the data is correct since according to your arguments against my position the data itself is not broad enough to draw any conclusions? Jim